LY-272,015

LY-272,015
Clinical data
Other names	LY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole
Identifiers
	IUPAC name 1-(3,4-dimethoxybenzyl)-6-methyl-2,3,4,9-tetrahydro-1H-β-carboline;
CAS Number	172895-15-7 ;
PubChem CID	9929424;
ChemSpider	8105055;
UNII	5NV3JP3GP6;
CompTox Dashboard (EPA)	DTXSID701336801 DTXSID30432996, DTXSID701336801 ;
Chemical and physical data
Formula	C21H24N2O2
Molar mass	336.435 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c4cc(C)cc3c4[nH]c2c3CCNC2Cc(cc1OC)ccc1OC;
	InChI InChI=1S/C21H24N2O2/c1-13-4-6-17-16(10-13)15-8-9-22-18(21(15)23-17)11-14-5-7-19(24-2)20(12-14)25-3/h4-7,10,12,18,22-23H,8-9,11H2,1-3H3; Key:GDAJGLDMCDMPIR-UHFFFAOYSA-N;
	(verify)

LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT_2B receptor. It has anti-hypertensive effects in animal models,^[1]^[2] and is also used in research into the other functions of the 5-HT_2B receptor.^[3]

References

^ Watts SW, Fink GD (March 1999). "5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats". The American Journal of Physiology. 276 (3): H944-52. doi:10.1152/ajpheart.1999.276.3.H944. PMID 10070078. S2CID 13301249.
^ Russell A, Banes A, Berlin H, Fink GD, Watts SW (October 2002). "5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat". The Journal of Pharmacology and Experimental Therapeutics. 303 (1): 179–87. doi:10.1124/jpet.102.037390. PMID 12235249. S2CID 98055109.
^ Günther S, Maroteaux L, Schwarzacher SW (August 2006). "Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro" (PDF). Journal of Neurobiology. 66 (9): 949–61. doi:10.1002/neu.20253. PMID 16758492. S2CID 26716284.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.